Alternatives to Entrectinib If You Can't Fill Your Prescription

Entrectinib (Rozlytrek) is an effective targeted therapy for ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors — but access barriers like prior authorization delays, specialty pharmacy network issues, and cost can leave patients searching for alternatives. This guide covers the FDA-approved options and what to discuss with your oncologist.

Important: Always Consult Your Oncologist Before Switching

Targeted oncology therapy is highly individualized. The right alternative depends on your specific cancer type, biomarker profile, brain metastasis status, prior treatments, side effect tolerance, and insurance coverage. This article provides general information — your oncologist must make the final call on any treatment change.

Alternatives for ROS1-Positive Non-Small Cell Lung Cancer

For adults with ROS1-positive metastatic NSCLC, three other tyrosine kinase inhibitors (TKIs) are FDA-approved:

1. Repotrectinib (Augtyro)

Repotrectinib (brand name Augtyro, made by Bristol Myers Squibb) was FDA-approved in November 2023 for ROS1-positive NSCLC and NTRK fusion-positive solid tumors. In clinical trials (TRIDENT-1), TKI-naïve patients achieved a median progression-free survival of 31.1 months — significantly longer than entrectinib's reported 15–17 months in comparable populations. It also demonstrated strong intracranial activity, with an 89% intracranial response rate in patients with measurable brain metastases. The tradeoff: repotrectinib causes more neurological side effects (dizziness in 62% of patients vs. 37% with entrectinib, and ataxia in 21% vs. 5%).

2. Taletrectinib (Ibtrozi)

Taletrectinib (brand name Ibtrozi) is a newer next-generation ROS1 TKI that has shown remarkable progression-free survival data in the TRUST-I trial (median PFS of 49.6 months in TKI-naïve patients). It has gained significant attention in the oncology community and has been increasingly used as a first-line option for ROS1-positive NSCLC. Ask your oncologist if taletrectinib may be appropriate for your case and whether your insurer covers it.

3. Crizotinib (Xalkori)

Crizotinib (brand name Xalkori, made by Pfizer) was the first FDA-approved TKI for ROS1-positive NSCLC (approved March 2016). It has a well-established safety profile and is taken orally twice daily at 250 mg. Its main limitation is poor central nervous system (CNS) penetration — the CNS is a site of progression in roughly half of patients on crizotinib. It may still be an option for patients who cannot tolerate the neurological side effects of newer ROS1 TKIs.

Alternatives for NTRK Gene Fusion-Positive Solid Tumors

For patients with NTRK gene fusion-positive solid tumors, there is one key alternative:

Larotrectinib (Vitrakvi)

Larotrectinib (brand name Vitrakvi, made by Bayer) was FDA-approved in November 2018 and is indicated for adults and pediatric patients with solid tumors harboring an NTRK gene fusion. Unlike entrectinib, larotrectinib is a highly selective TRK inhibitor — it does not target ROS1 or ALK. Many oncologists consider larotrectinib to have more robust clinical data for NTRK fusion cancers. It is taken orally twice daily (100 mg twice daily for adults) and is generally well-tolerated.

Side-by-Side Comparison: Key Differences

Entrectinib (Rozlytrek): TRK + ROS1 + ALK; once daily 600 mg; CNS active; approved 2019

Repotrectinib (Augtyro): TRK + ROS1 + ALK; once daily; stronger CNS activity; more neurologic side effects; approved 2023

Taletrectinib (Ibtrozi): ROS1 TKI; strong PFS data; newer to market

Crizotinib (Xalkori): ROS1 + ALK; twice daily; limited CNS penetration; well-established tolerability; approved 2016

Larotrectinib (Vitrakvi): TRK-selective only; twice daily; does NOT cover ROS1; approved 2018

What If None of These Are Accessible Either?

Clinical trials may be an option if approved therapies are inaccessible or have stopped working. Ask your oncologist whether you qualify for any open trials. The ClinicalTrials.gov website lists all active studies and eligibility requirements.

The Bottom Line

If you're having trouble filling your entrectinib prescription, don't stop treatment without guidance from your oncologist. Start by working through access solutions (Genentech, specialty pharmacies), and see our guide on how to find entrectinib in stock near you. And if you need help locating a pharmacy that can fill any of these medications, medfinder contacts pharmacies on your behalf to find out which ones have your medication available.